Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / *W EXP 12/17/202
-
Total 13F shares
-
8,041,860
-
Share change
-
+394,539
-
Total reported value
-
$2,116,552
-
Price per share
-
$0.26
-
Number of holders
-
21
-
Value change
-
+$143,332
-
Number of buys
-
4
-
Number of sells
-
4
Institutional Holders of Revolution Medicines, Inc. - *W EXP 12/17/202 (RVMDW) as of Q2 2025
As of 30 Jun 2025,
Revolution Medicines, Inc. - *W EXP 12/17/202 (RVMDW) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,041,860 shares.
The largest 10 holders included
LMR Partners LLP, D. E. Shaw & Co., Inc., PRICE T ROWE ASSOCIATES INC /MD/, ADAGE CAPITAL PARTNERS GP, L.L.C., Lunate Capital Ltd, SOROS CAPITAL MANAGEMENT LLC, ARISTEIA CAPITAL, L.L.C., PERCEPTIVE ADVISORS LLC, TORONTO DOMINION BANK, and Bleichroeder LP.
This page lists
21
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.